Clinical Trial Update: Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of ADL5945 for opioid-induced constipation in adults on chronic opioid therapy has completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid-induced Constipation

Drugs mentioned

• ADL5945 (ADL5945)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Opioid Induced Constipation | Phase 2 | Status: COMPLETED | Results posted: 2015-05-07